Search Results (36)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. | Academic Article |
Why?
|
| PharmVar GeneFocus: CYP2C19. | Academic Article |
Why?
|
| Gaedigk, Andrea | Person |
Why?
|
| Cytochrome P-450 CYP2C19 | Concept |
Why?
|
| Cytochrome P-450 CYP2C19 Inducers | Concept |
Why?
|
| Cytochrome P-450 CYP2C19 Inhibitors | Concept |
Why?
|
| Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. | Academic Article |
Why?
|
| Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. | Academic Article |
Why?
|
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. | Academic Article |
Why?
|
| Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. | Academic Article |
Why?
|
| Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project. | Academic Article |
Why?
|
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. | Academic Article |
Why?
|
| Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. | Academic Article |
Why?
|
| Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. | Academic Article |
Why?
|
| Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". | Academic Article |
Why?
|